Moderna shares dip amid rising selling pressure

Traders Union
All News
Financial News
Moderna slides 3.29% today to $49.06

Highlights

Moderna faces multiple patent infringement lawsuits from BioNTech and CureVac over its mRNA COVID-19 vaccine technology.
The FDA has accepted Moderna’s mRNA-1010 seasonal flu vaccine candidate for regulatory review, but the stock remains pressured.
Moderna trades below key moving averages with mixed momentum signals, expected to move between $45.67 and $51.32 in the next week.

Ongoing legal challenges and FDA review heighten market caution

Moderna is facing multiple patent infringement lawsuits over its mRNA-based COVID-19 vaccine Spikevax, with BioNTech and CureVac both alleging unauthorized use of patented technologies. Moderna has stated its intention to defend itself against these claims. Its mRNA-1010 seasonal influenza vaccine candidate was formally accepted for regulatory review by the FDA, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Moderna’s recent slide below the 20-day and 50-day moving averages exposes the stock's fragility in the short and medium term. He highlights the ongoing legal battles over vaccine patents as a key risk factor which may weigh on sentiment and further unsettle investors. Pressure from oversold technical indicators and mixed momentum signals suggest that buyers lack conviction for a sustained rebound. Kharitonov cautions that a break below $45.67 could trigger accelerated downside, especially if litigation risks intensify. "I see more downside risk in the current environment, with negative sentiment and unresolved legal threats keeping buyers on the defensive."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s mRNA portfolio and regulatory milestones position the company well for further growth. He sees the stock’s hold above the 200-day moving average as confirmation that the longer-term bullish structure remains intact. The recent FDA review acceptance of the mRNA-1010 vaccine is a positive signal, despite short-term volatility. Karapetjanc emphasizes that strong weekly technicals and resilient fundamentals create attractive setups for constructive investors. "The market offers multiple opportunities here — I expect a recovery toward $51.32 as confidence returns."

Parshwa Turakhiya, analyst, sees a sentiment-driven selloff dominating the short-term action in Moderna. He points out that oversold oscillators and a downside gap indicate near-term pessimism but also set the stage for a technical bounce. The volatility band between $45.67 and $51.32 presents short-term trading opportunities both ways. Turakhiya says, "With sellers in control but oversold signals flashing, nimble traders should watch for a quick momentum shift in the coming sessions."

Mixed momentum and oversold levels amid persistent selling

Moderna is currently trading below the 20-day and 50-day moving averages (MA-20 at $51.76, MA-50 at $51.55) but remains well above the 200-day moving average at $35.36, indicating short- and medium-term selling pressure, with the long-term trend still supportive. The closest dynamic resistance sits at the Ichimoku Kijun level of $51.67, with longer-term support found near the 200-day moving average. Momentum signals are mixed on the day: the Moving Average Convergence Divergence (MACD) shows a strong buy, yet the Relative Strength Index (RSI) signals selling and sits below 50, and the Average Directional Index (ADX) is moderately bullish. Stochastic RSI and Commodity Channel Index (CCI) both highlight deep oversold conditions. Bull/Bear Power (BBP) points to ongoing buyer dominance on the daily timeframe, though intraday signals indicate overbought conditions earlier but a recent oversold turn. The Awesome Oscillator is currently neutral. The stock is down 3.29% to $49.06 with a downside opening gap of about $0.10, now trading near the session’s low. Intraday volatility stands at 4.61%, with sustained pressure after the open as sellers control momentum. The divergence between oversold oscillators and strong daily momentum highlights the possibility of a short-term technical rebound, but immediate sentiment remains negative.

Earlier, analysts noted that while Moderna was demonstrating positive long-term momentum supported by strategic partnerships and regulatory progress, the stock continued to encounter short-term selling pressure amid legal uncertainties. The current analysis reinforces this dynamic, highlighting that despite near-term weakness and ongoing patent disputes, a technical rebound remains plausible, with market participants advised to monitor the $45.67 support and $51.67 resistance levels for potential directional shifts in the days ahead.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.